Polyclonal antibodies are immunoglobulin that bind nonspecifically to multiple epitopes of an antigen. They are commonly produced by injecting the antigen into an animal and harvesting the resulting serum containing the immunoglobulin. Factors such as the rising prevalence of various chronic and infectious diseases, increasing research and development investments in the pharmaceutical and biotechnology sectors, and the growing adoption of polyclonal antibodies for research applications are expected to drive the growth of this market. However, stringent regulatory guidelines for product approval may impede market growth to some extent. Polyclonal antibodies are a heterogeneous mix of antibodies derived from the immune response of multiple B-cells, in which each one recognizes a different epitope on the same antigen. Polyclonal antibodies are composed of a mixture of antibodies that represent the natural immune response to an antigen. Polyclonal antibodies are used in general research applications
Market Dynamics:
The global polyclonal antibody market is projected to grow at a steady pace during the forecast period owing to various driving factors such as rising prevalence of chronic and infectious diseases, and growing adoption in various research applications. Furthermore, ongoing innovations in diagnostic technology and a rapid shift towards polyclonal antibodies as an inexpensive alternative to monoclonal antibodies are expected to boost demand. However, the high costs associated with the purification and heterogeneity of polyclonal antibodies along with stringent regulatory approvals, pose major challenges to the market. On the other hand, development of advanced purification techniques, labeling processes, and recombinant antibody production creates growth opportunities during the forecast period
Key features of the study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook